GlassScriptPhysician profile
Timothy S Morse
NPI 1811130867
$5,473.01
in general payments reported to CMS, 2019-2025
36 companies · $780 in 2025
The $780 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,630 · 2022: $1,285 · 2023: $1,030 · 2024: $747 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,557.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $785.64 | 2021-2025 | |
| Amgen INC. | $590.49 | 2021-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $557.52 | 2021-2025 | |
| Lilly USA, LLC | $454.18 | 2021-2025 | Mounjaro, Zepbound, Reyvow |
| Novo Nordisk INC | $296.42 | 2021-2025 | Wegovy, Saxenda, Ozempic |
| Otsuka America Pharmaceutical, INC. | $243.54 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $241.04 | 2021-2025 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $220.06 | 2021 | |
| Lundbeck LLC | $184.43 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $183.28 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.08 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $154.36 | 2021-2024 | Belsomra, Verquvo, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.51 | 2021-2023 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $138.90 | 2021-2023 | Nexletol |
| Exact Sciences Corporation | $136.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $124.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $109.64 | 2021-2023 | |
| Dexcom, INC. | $106.88 | 2024-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $82.02 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $68.36 | 2021-2022 | |
| Antares Pharma, INC. | $61.93 | 2021-2025 | Xyosted |
| Teva Pharmaceuticals USA, INC. | $60.42 | 2022-2023 | Ajovy, Austedo |
| Glaxosmithkline, LLC. | $59.93 | 2022 | |
| Supernus Pharmaceuticals, INC. | $48.36 | 2021 | Tlando, Xyosted |
| Corium, LLC | $42.33 | 2022-2023 | Azstarys |
| Mylan Specialty L.P. | $34.49 | 2021-2024 | Yupelri |
| Halozyme INC | $30.93 | 2023 | |
| Horizon Therapeutics Plc | $29.31 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.80 | 2025 | |
| Astellas Pharma US INC | $19.34 | 2024 | Veozah |
| Almatica Pharma LLC | $18.26 | 2021 | |
| Viatris Specialty LLC | $15.52 | 2025 | Yupelri |
| Sunovion Pharmaceuticals INC. | $14.54 | 2021 | |
| Abbott Laboratories | $14.07 | 2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $14.06 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.36 | 2023 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Morse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.